ClinicalTrials.gg
CompletedNCT01835899Updated Jan 22, 2016Results posted

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

A Phase 1 interventional study of Placebo and BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

To investigate safety, tolerability, and pharmacokinetics of multiple rising oral doses of BI 1015550 in healthy male volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
  2. Subjects unable to understand or to comply with study requirements
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Placebo to BI 1015550

    placebo

    Drug: Placebo

  • Experimental
    BI 1015550 low dose 1

    powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 low dose 2

    powder for oral solution

    Drug: BI1015550

  • Experimental
    BI 1015550 medium dose 1

    powder for oral solution

    Drug: BI 1015550

  • Experimental
    BI 1015550 medium dose 2

    powder for oral solution

    Drug: BI 1015550

Interventions

  • DrugPlacebo

    Placebo to BI 1015550

  • medium dose 1 powder for oral solution

  • medium dose 2 powder for oral solution

  • low dose 2 powder for oral solution

  • low dose 1 powder for oral solution

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Drug-related Adverse Events

    Percentage of subjects with drug related Adverse events, as assessed by the investigator.

    Time frame: From first drug administration until last drug administration, upto 18 days.

Secondary outcomes

  1. Cmax

    Maximum measured concentration of BI 1015550 in plasma.

    Time frame: 0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h; 12h; 24h; 34h and 47:55h after first drug administration.

  2. AUCt,1

    Area under the concentration-time curve of BI 1015550 in plasma over a uniform dosing interval t after administration of the first dose

    Time frame: 0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h and 12h after first drug administration

  3. AUC0-infinity

    Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity.

    Time frame: 0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h; 12h; 24h; 34h and 47:55h after first drug administration.

  4. Cmax,ss

    Maximum measured concentration of BI 1015550 in plasma at steady state over a uniform dosing interval t.

    Time frame: 311:55h (hours); 312:15h; 312:30h; 312:45; 313h; 313:15h; 313:30h; 314h; 315h; 316h; 318h; 320h; 322h; 324h; 336h; 346h; 360h; 384h & 408h after first drug administration; last drug administration was at 312 h.

  5. AUCt,ss

    Area under the concentration-time curve of BI 1015550 in plasma at steady state over a uniform dosing interval t.

    Time frame: 311:55h; 312:15h; 312:30h; 312:45; 313h; 313:15h; 313:30h; 314h; 315h; 316h; 318h; 320h; 322h and 324h after first drug administration; last drug administration was at 312 h.

07

Results

Posted Jan 22, 2016
Limitations and caveats
The study was prematurely completed as per protocol after 2 of the originally planned 4 dose groups ie., 1 mg BI 1015550 and 6 mg BI 1015550 because of higher than expected drug exposure.

Participant flow

Participant flow — Overall Study
MilestonePlacebo to BI 10155501 mg BI 10155506 mg BI 1015550
Started699
Completed688
Not completed011
Withdrew: Adverse event001
Withdrew: Other than stated above010

Outcome measures

PrimaryPercentage of Subjects With Drug-related Adverse Events

Percentage of subjects with drug related Adverse events, as assessed by the investigator.

Time frame:
From first drug administration until last drug administration, upto 18 days.
Reported as:
Number · Percentage of participants
Percentage of Subjects With Drug-related Adverse Events
Percentage of participantsPlacebo to BI 10155501 mg BI 10155506 mg BI 1015550
Percentage of Subjects With Drug-related Adverse Events16.744.411.1
SecondaryCmax

Maximum measured concentration of BI 1015550 in plasma.

Time frame:
0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h; 12h; 24h; 34h and 47:55h after first drug administration.
Reported as:
Geometric mean · nmol/L
Cmax
nmol/L1 mg BI 10155506 mg BI 1015550
Cmax24.0 ± 25.1133.0 ± 14.9
SecondaryAUCt,1

Area under the concentration-time curve of BI 1015550 in plasma over a uniform dosing interval t after administration of the first dose

Time frame:
0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h and 12h after first drug administration
Reported as:
Geometric mean · nmol*h/L
AUCt,1
nmol*h/L1 mg BI 10155506 mg BI 1015550
AUCt,194.9 ± 10.3622 ± 20.7
SecondaryAUC0-infinity

Area under the concentration-time curve of BI 1015550 in plasma over the time interval from 0 extrapolated to infinity.

Time frame:
0:15h(hours); 0:30h; 0:45h; 1h;1:15h;1:30h; 2h;3h; 4h; 6h; 8h;10h; 12h; 24h; 34h and 47:55h after first drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity
nmol*h/L1 mg BI 10155506 mg BI 1015550
AUC0-infinity131 ± 18.6958 ± 20.9
SecondaryCmax,ss

Maximum measured concentration of BI 1015550 in plasma at steady state over a uniform dosing interval t.

Time frame:
311:55h (hours); 312:15h; 312:30h; 312:45; 313h; 313:15h; 313:30h; 314h; 315h; 316h; 318h; 320h; 322h; 324h; 336h; 346h; 360h; 384h & 408h after first drug administration; last drug administration was at 312 h.
Reported as:
Geometric mean · nmol/L
Cmax,ss
nmol/L1 mg BI 10155506 mg BI 1015550
Cmax,ss28.6 ± 15.3199 ± 14.5
SecondaryAUCt,ss

Area under the concentration-time curve of BI 1015550 in plasma at steady state over a uniform dosing interval t.

Time frame:
311:55h; 312:15h; 312:30h; 312:45; 313h; 313:15h; 313:30h; 314h; 315h; 316h; 318h; 320h; 322h and 324h after first drug administration; last drug administration was at 312 h.
Reported as:
Geometric mean · nmol*h/L
AUCt,ss
nmol*h/L1 mg BI 10155506 mg BI 1015550
AUCt,ss148 ± 10.71090 ± 19.6

Adverse events

Collected over From first drug administration until last drug administration, upto 18 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo to BI 1015550—0/6 (0%)1/6 (16.7%)
1 mg BI 1015550—0/9 (0%)4/9 (44.4%)
6 mg BI 1015550—0/9 (0%)1/9 (11.1%)
Most frequent other events
Most frequent other events
EventPlacebo to BI 10155501 mg BI 10155506 mg BI 1015550
HeadacheNervous system disorders1/61/90/9
Abdominal painGastrointestinal disorders0/61/91/9
Abdominal pain lowerGastrointestinal disorders0/60/91/9
Aphthous stomatitisGastrointestinal disorders0/61/90/9
ConstipationGastrointestinal disorders0/60/91/9
DiarrhoeaGastrointestinal disorders0/61/90/9
Oral herpesInfections and infestations0/61/90/9
ContusionInjury, poisoning and procedural complications0/60/91/9
Traumatic haematomaInjury, poisoning and procedural complications0/60/91/9
C-reactive protein increasedInvestigations0/60/91/9

Baseline characteristics

The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)Placebo to BI 10155501 mg BI 10155506 mg BI 1015550Total
Mean43.5 ± 9.938.7 ± 8.544.3 ± 8.342.0 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Placebo to BI 10155501 mg BI 10155506 mg BI 1015550Total
Female0000
Male69924
08

Study locations

1 site
  • 1305.2.1 Boehringer Ingelheim Investigational Site
    Mannheim, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2013
First posted
Apr 19, 2013
Start
Apr 2013
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Jan 22, 2016
Last update
Jan 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01835899
Responsible party
Sponsor
First posted
Apr 19, 2013
Start date
Apr 2013
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Jan 22, 2016
Last update
Jan 22, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion